These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10500576)

  • 21. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients.
    Weber M; Ketchum RJ; Sellers M; Aradhye S; Deng S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
    Transplant Proc; 1997; 29(1-2):338-9. PubMed ID: 9123029
    [No Abstract]   [Full Text] [Related]  

  • 22. Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection.
    Ferraris JR; Tambutti ML; Redal MA; Bustos D; Ramirez JA; Prigoshin N
    Transplantation; 2000 Jul; 70(2):297-301. PubMed ID: 10933152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. International Mycophenolate Mofetil Renal Study Groups.
    Cho S; Hodge E; Navarro M
    Transplant Proc; 1999; 31(1-2):322-3. PubMed ID: 10083126
    [No Abstract]   [Full Text] [Related]  

  • 25. Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction.
    Senn B; Rochat P; Schwarzkopf AK; Weinreich T; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4075-6. PubMed ID: 9865301
    [No Abstract]   [Full Text] [Related]  

  • 26. The case of azathioprine versus mycophenolate. Do different drugs really cause different transplant outcomes?
    Craig JC; Webster AC; McDonald SP
    Transplantation; 2009 Mar; 87(6):803-4. PubMed ID: 19300180
    [No Abstract]   [Full Text] [Related]  

  • 27. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function.
    Fritsche L; Sperschneider H; Budde K; Giessing M; Türk H; Böhler T; Schröder K; Stein G; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):2229. PubMed ID: 9723451
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison between mycophenolate mofetil and azathioprine based immunosuppression in pediatric renal transplantation from living related donors.
    Antoniadis A; Papachristou F; Gakis D; Takoudas D; Sotiriou I
    Transplant Proc; 1998 Dec; 30(8):4085-6. PubMed ID: 9865305
    [No Abstract]   [Full Text] [Related]  

  • 29. Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study.
    Campistol JM; Mazuecos A; Segura J; Osuna A; Herrero JC; Andres A; Oppenheimer F; Gomez de la Camara A; Martinez MA; Morales JM
    Transplant Proc; 1999 Sep; 31(6):2267-9. PubMed ID: 10500571
    [No Abstract]   [Full Text] [Related]  

  • 30. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in long-term graft survival in cadaveric renal transplant recipients treated with mycophenolate mofetil.
    Hazzan M; Provot F; Glowacki F; Copin MC; Roumilhac D; Labalette M; Pruvot FR; Noel C
    Transpl Int; 2004 Oct; 17(9):525-30. PubMed ID: 15338120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.
    Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S; Chiewsilp P; Leenanupunth C; Kochakarn W
    Transplant Proc; 1998 Nov; 30(7):3576-7. PubMed ID: 9838566
    [No Abstract]   [Full Text] [Related]  

  • 33. One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation.
    Khosla UM; Martin JE; Baker GM; Schroeder TJ; First MR
    Transplant Proc; 1999; 31(1-2):274-5. PubMed ID: 10083105
    [No Abstract]   [Full Text] [Related]  

  • 34. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 35. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of renal transplantation with different immunosuppressive regimens.
    Folkmane I; Bicans J; Chapenko S; Murovska M; Rosentals R
    Transplant Proc; 2002 Mar; 34(2):558-9. PubMed ID: 12009623
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic drug level monitoring for mycophenolate mofetil: is it justified?
    Stephan A; Masri MA; Barbari A; Kamel G; Karam A; Kilani H
    Transplant Proc; 2001 Aug; 33(5):2778-9. PubMed ID: 11498157
    [No Abstract]   [Full Text] [Related]  

  • 38. Mycophenolate mofetil use is associated with prolonged graft survival after kidney transplantation.
    Kainz A; Heinze G; Korbély R; Schwarz C; Oberbauer R
    Transplantation; 2009 Nov; 88(9):1095-100. PubMed ID: 19898205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
    Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
    [No Abstract]   [Full Text] [Related]  

  • 40. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
    Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
    Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.